Mar 1, 2017 • 7:30 am EST Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
Feb 23, 2017 • 8:05 am EST Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Feb 21, 2017 • 7:30 am EST Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017
Jan 17, 2017 • 7:30 am EST Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union
Dec 29, 2016 • 7:30 am EST Corbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis
Nov 29, 2016 • 7:30 am EST Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
Nov 14, 2016 • 6:30 am EST Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis